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ABSTRACT
Progression of castration-resistant tumors is frequent in prostate cancer. Current 
systemic treatments for castration-resistant prostate cancer only produce modest 
increases in survival time and self-renewing Tumor-Initiating Cells (TICs) are suspected 
to play an important role in resistance to these treatments. However it remains unclear 
whether the same TICs display both chemo-resistance and self-renewing abilities 
throughout progression from early stage lesions to late, castration resistant tumors. 
Here, we found that treatment of mice bearing LNCaP-derived xenograft tumors with 
cytotoxic (docetaxel) and anti-androgen (flutamide) compounds enriched for cells 
that express TROP2, a putative TIC marker. Consistent with a tumor-initiating role, 
TROP2high cells from androgen-sensitive prostate cancer cell lines displayed an enhanced 
ability to re-grow in culture following treatment with taxane-based chemotherapy 
with or without androgen blockade. TROP2 down-regulation in these cells reduced 
their ability to recur after treatment with docetaxel, in the presence or absence of 
flutamide. Accordingly, in silico analysis of published clinical data revealed that prostate 
cancer patients with poor prognosis exhibit significantly elevated TROP2 expression 
level compared to low-risk patients, particularly in the case of patients diagnosed with 
early stage tumors. In contrast, in androgen-independent prostate cancer cell lines, 
TROP2high cells did not exhibit a differential treatment response but were characterized 
by their high self-renewal ability. Based on these findings we propose that high TROP2 
expression identifies distinct cell sub-populations in androgen-sensitive and androgen-
independent prostate tumors and that it may be a predictive biomarker for prostate 
cancer treatment response in androgen-sensitive tumors.
INTRODUCTION
Prostate cancer is second to lung cancer in incidence 
worldwide, and is the third most common cause of 
cancer death in developed countries [1]. Small prostatic 
carcinomas can be detected in up to 29% of men aged 
30 to 40 years and 64% of men aged 60-70 years [2]. 
Androgen deprivation is the mainstay of treatment for men 
with locally advanced or metastatic disease, but surviving 
cancer cells frequently become highly aggressive and 
metastatic, and resistant to further treatment [3]. A small 
population of prostate cancer cells with tumor-initiating 
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cell properties has been shown to harbor intrinsic 
characteristics that make them resistant to androgen 
deprivation and chemotherapy [4, 5]. Since they also 
display a robust self-renewing ability and appear to drive 
tumor progression, their identification, characterization 
and elimination would provide a significant therapeutic 
advantage, but little is known on how the chemo-resistance 
and self-renewing abilities of prostate TICs evolve during 
progression from early androgen-sensitive lesions to late, 
castration resistant tumors.
Several combinations of markers have been 
proposed to identify prostate tumor-initiating cells. 
Such molecular signatures include surface expression of 
CD133 [6], CD49f, Sca-1 [7], CD44 [8] and the enzymatic 
activity of aldehyde dehydrogenase (ALDH) [9]. High 
expression of the cell surface glycoprotein TROP2 has 
been reported in sphere-forming, stem/progenitor prostate 
epithelial cells [10, 11], where its activity may contribute 
to enhance self-renewal and drive hyperplasia [12]. 
TROP2 is frequently upregulated in prostate carcinoma 
and appears to promote metastasis via the modulation of 
β1 integrin [13]. However, it remains unclear whether 
TROP2 marks tumor-initiating cells in androgen-sensitive 
and castration resistant prostate tumors and if it plays a 
role in the resistance of these cells to therapy.
To address this we investigated the expression 
and function of TROP2 in androgen-sensitive and 
-resistant prostate cancer cells. We found that TROP2high 
tumor cells were enriched following treatment of 
LNCaP-derived prostate cancer xenografts. Cells with 
extracellular membrane expression of TROP2 displayed 
different properties in androgen-sensitive and androgen-
independent cellular contexts. In androgen-sensitive 
populations TROP2high cells displayed an enhanced ability 
to withstand treatment with high concentrations of taxane-
based chemotherapy with or without androgen blockade, 
while in androgen-independent prostate cancer cells high 
TROP2 expression marked a highly self-renewing cell 
sub-population that showed no differential response to 
treatment.
TROP2 down-regulation increased the 
sensitivity of androgen-sensitive cells to docetaxel, 
in the presence or the absence of the anti-androgen 
compound flutamide. Analysis of published clinical 
data indicated that high TROP2 expression correlated 
with poorer recurrence-free survival in prostate 
cancer patients. In particular, patients with low grade 
(Gleason 6) tumors that expressed high TROP2 mRNA 
levels had significantly worse prognosis compared 
to those with tumors expressing low TROP2 levels. 
Based on these findings we propose that high TROP2 
expression identifies TIC sub-populations with different 
phenotypes in androgen-sensitive and androgen-
independent prostate tumors and that it may represent 
a worthwhile predictive biomarker for prostate cancer 
treatment response in androgen-sensitive tumors.
RESULTS
TROP2 expression levels correlates with disease 
outcome in prostate cancer patients
We first analyzed the expression of TROP2 using IHC 
in a small subset of prostate tumors with increasing Gleason 
grade. Regardless of the Gleason grade, TROP2 was mostly 
expressed by basal layer cells of the prostate epithelium. 
No significant difference in TROP2 expression was detected 
among our samples (Figure 1A), suggesting that a minority 
of tumor cells express TROP2 during all stages of prostate 
tumor progression. In addition, we mined the SurvExpress 
Web resource [14] to determine whether TROP2 expression 
level in prostate tumors at the time of surgery was correlated 
with specific disease outcomes in previously published 
datasets. Patients with high tumor TROP2 expression 
displayed significantly worse recurrence-free survival than 
those expressing low levels of TROP2 in a small population 
of prostate cancer patients [15] (p=0.03995, n=89, Figure 
1B). Using a larger dataset [16] we analyzed whether a 
similar distinction between TROP2-high and TROP2-low 
tumors could be detected irrespective of Gleason grading, 
the main current prognostic indicator in prostate cancer. 
We found that significantly elevated TROP2 expression 
characterized a subgroup with significantly worse overall 
survival in patients with early stage prostate tumors 
(Gleason 6, p=0.006536, n=77) (Figure 1C), while TROP2 
levels were not significantly correlated with differences in 
survival for other Gleason grades (Supplementary Figure 
S1). Taken together, our findings suggest that TROP2-
expressing cells are detectable across all prostate cancer 
stages but that differences of TROP2 expression levels 
among patients may highlight a worse prognosis for prostate 
cancer patients, particularly for those diagnosed with early 
stage tumors.
TROP2 expression in tumors from LNCaP 
xenografts treated with flutamide and docetaxel
In view of the poorer prognosis exhibited by TROP2-
high low-grade tumors, we aimed to determine whether 
TROP2 expression is associated with chemoresistance in 
androgen-sensitive tumor cells. To do so androgen-sensitive 
LNCaP cells were xenografted into NOD/SCID mice, and 
recurrence after treatment with docetaxel chemotherapy 
(10 mg/kg/week) and/or with the anti-androgen compound 
flutamide (33 mg/kg/day) was investigated. Treatment 
commenced when tumors reached 100mm3 and tumor 
volume was measured to determine the growth rate of 
tumors under different treatment conditions. Efficacy 
of docetaxel and flutamide treatments was corroborated 
by their respective impact on testes and prostate weight 
compared to control mice (Supplementary Figure S2).
Flutamide treatment did not induce a regression of 
tumor volume but slowed down tumor growth (day 0: 
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114.8 ± 2.5mm3; day 49: 603.5 ± 60.1mm3) compared 
to the control group (day 0: 108.5±0.4 mm3, day 49: 
1438.0 ± 609.7mm3) (P = 0.0009) (Figure 2A). Docetaxel 
alone or in combination with flutamide decreased 
tumor volume (Figure 2B), and post-treatment tumor 
recurrence was delayed in mice treated with docetaxel 
alone compared to those who received a combination of 
flutamide and docetaxel (P = 0.0406). At day 21 (end 
of docetaxel treatment), mice from both groups had 
similar tumor volumes (docetaxel: 45.6 ± 13.9mm3; 
combined: 51.8 ± 13.5mm3 P = 0.3512), but after 
docetaxel treatment had finished, tumor volume in mice 
treated with docetaxel alone continued to decrease (day 
35: 24.9 ± 5.0mm3) whereas mice from the combination 
Figure 1: A. Representative microphotograph depicting tumors cells positively stained with selective antibodies against TROP2 (left) 
and the androgen receptor (AR, right) in a human prostate carcinoma slide, compared with the same slide stained with the isotype control 
antibodies. Scale bars = 50μm. B. Top, frequency of cells displaying TROP2 staining at the cell membrane (expressed as percent of tumor 
cells) in tissue sections from 5 patients (P1-5) with prostate carcinoma (P1: unknown Gleason grade; P2: Gleason >9; P3: Gleason = 9; P4: 
Gleason = 6; P5: Gleason = 6); Bottom, pie chart summarizing the mean percentage of TROP2 positive and TROP2 negative cells across 
all patients. C. Kaplan-Meier curve showing the recurrence-free survival (left) and box-plot showing TROP2 expression levels (right) in 
Low and High risk prostate cancer patient groups (Data from GSE40272, total number of samples = 89). Expression data is provided as 
median and 5-95 percentile in each patient group. D. Kaplan-Meier curve showing the overall survival (left) and box-plot showing TROP2 
expression levels (right) in Low and High risk groups from patients with Gleason 6 prostate cancer (Data from GSE40272, total number of 
samples for this grade = 77). In C and D, hazard ratios with their confidence interval are provided (left), as well as p values for the log-rank 
testing equality of survival curves (left) and for the difference between TROP2 expression in low- and high-risk groups, using t-test (right). 
TROP2 expression data is provided as median and 5-95 percentile in each patient group.
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treatment group maintained a steady tumor size (day 
35: 52.0 ± 18.6mm3) (P = 0.0454). RT-qPCR was used 
to quantify the expression of TROP2 mRNA as well 
as that of putative markers for basal/cancer stem cells 
(CD49f, POU5F1 (Oct4), DCLK1, ALDH1A3) or 
luminal stem cells (NKX3.1) [17] in residual tumors 
(Figure 2C). Expression of TROP2 and DCLK1 mRNAs 
was robustly up-regulated in tumors following relapse 
from the combination treatment of flutamide and 
docetaxel, while recurring tumors showed no change 
in CD49f, Oct4, NKX3.1 or ALDH1A3 (Figure 2C). 
High extracellular TROP2 expression was also detected 
by immunohistochemistry in tumors that underwent 
combination treatment (Figure 2D). These findings 
demonstrate that TROP2 is enriched in tumor cells that 
recur after treatment of androgen-sensitive xenografts 
with docetaxel/androgen ablation combination therapy.
Androgen-sensitive TROP2high prostate cancer 
cells display higher resistance to high dose 
chemotherapy and androgen deprivation
Because Tumor-Initiating Cells (TICs) are thought 
to play a role in enhanced treatment resistance, we then 
investigated whether cells demonstrating high levels of 
membrane TROP2 expression exhibit TIC properties in 
androgen-sensitive human prostate cancer cells. LNCaP 
cells that highly expressed extracellular TROP2 did not 
stand out as a separate population. Instead, cells presented 
with a continuum of low to high extracellular TROP2 levels, 
and the top 2% of cells with the brightest fluorescence after 
labeling with a selective antibody were chosen as TROP2high 
cells (Figure 3A). Baseline growth was similar in TROP2high, 
TROP2low and ungated LNCaP cells (Supplementary 
Figure S2). Extreme Limiting Dilution Analysis showed 
Figure 2: A–B. Tumor growth in NOD/SCID mice treated with vehicle (control), 33mg/kg/day flutamide (FLT), 10mg/kg/week docetaxel 
(DTX) or a combination of docetaxel and flutamide (DTX + FLT), as indicated. Data was analyzed by two-way repeated measures ANOVA 
and a P value < 0.05 for the interaction between treatments and time was considered to be statistically significant (n = 5 mice/group). 
C. mRNA expression levels in prostate tumors derived from LNCaP cell xenografts treated as above. *, P<0.05 and ****, P<0.0001, 
significantly different from control and flutamide treatment groups. ##, P<0.01 and ####, P<0.0001, significantly different from docetaxel 
treatment group. D. Immunohistochemical staining of TROP2 on tumors derived from xenografts treated as indicated in (A) and (B). Scale 
bar=100µm.
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that there was no difference in sphere-forming efficiency 
(Table 1 and Supplementary Figure S2) between TROP2high, 
TROP2low and ungated LNCaP cells. This result indicates 
that TROP2high cells do not display enhanced self-renewal 
abilities compared to other cell populations, despite 
the mRNA enrichment for the putative tumor-initiating 
cell marker ALDH1A3 in TROP2high cells (Figure 3B). 
Similarly, no significant difference was detected between 
the sphere-forming efficiency of TROP2high and TROP2low 
and ungated cells from another androgen-sensitive cell 
line, 22Rv1, as determined using ELDA (Table 1 and 
Supplementary Figure S2). These results suggest that High 
TROP2 expression does not selectively enrich pre-existing 
cell populations with high self-renewal ability in androgen-
sensitive prostate cancer cells.
In order to analyze their response to therapeutic 
agents in vitro, TROP2high, TROP2low and ungated LNCaP 
cells were sorted by FACS and treated for 5 days with 
docetaxel alone or in combination with 10µM flutamide. 
Cell viability was assessed immediately after treatment 
cessation (Figure 3C) or 7 days after withdrawal of 
docetaxel (Figure 3D).
The number of residual live cells was significantly 
lower after a 7-day treatment withdrawal compared to 
straight after treatment cessation regardless of the cell 
population (Figure 3C–3D). Since docetaxel was the only 
compound present under all conditions this indicates that 
docetaxel-induced cell death continued well after the 
removal of this compound from the culture medium.
Dose-response curve analysis indicated that 
docetaxel decreased the viability of TROP2high, TROPlow 
and ungated LNCaP cells with similar IC50 (Supplementary 
Figure S3), suggesting that cytotoxic treatment kills these 
different cell populations with a similar potency.
However, when we analyzed the maximal effect 
of docetaxel (defined here as the mean percentage of 
Figure 3: A. FACS profile of LNCaP cells according to their surface TROP2 expression level. Black line: cells were stained mouse isotype 
control; red line: cells were stained with TROP2 antibody. B. RT-qPCR quantitation of TACSTD2 (TROP2), POU5F1 (Oct4), NKX3.1, 
and ALDH1A3 mRNA expression. DCLK1 was undetectable in these cells C. Percentage of viable TROP2high, TROP2low and ungated 
LNCaP cells at the end of a 5-day treatment with docetaxel alone (DTX, top) or in combination with flutamide (DTX + FLT, bottom). Data 
represents the mean percentage of surviving cells after exposure to the three highest concentrations of docetaxel (1nM, 10nM, 100nM). 
D. Percentage of viable TROP2high, TROP2low and ungated LNCaP cells after a 5-day treatment with docetaxel alone (DTX, top) or in 
combination with flutamide (DTX + FLT, bottom) followed by a 7-day recovery phase in docetaxel-free medium. Data represents the mean 
percentage of surviving cells after exposure to the three highest concentrations of docetaxel (1nM, 10nM, 100nM). In C and D: *, P < 0.05, 
**, P < 0.01, significantly different from TROP2low cells, one-way ANOVA with Bonferroni post-hoc, n=3.
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viable cells that remain after exposure to the three highest 
concentrations of docetaxel – 1nM, 10nM and 100nM), we 
found that a significantly higher percentage of TROP2high 
cells remained alive compared to TROP2low cells, both a 
the end of the high dose docetaxel treatment (DTX) or 
following a 7-day relapse (Figure 3C–3D). Our finding 
demonstrates that docetaxel kills TROP2high cells with 
a lower maximal efficacy compared to TROP2low cells. 
Similar results were also found for androgen-sensitive 
22Rv1 cells (Supplementary Figures S3 and S4).
When androgen-sensitive cells were incubated with 
docetaxel in the presence of flutamide (DTX + FLT), 
TROP2high 22Rv1 cells were again able to recover more 
efficiently from exposure to high docetaxel concentrations 
(Supplementary Figure S4), while this was not detected in 
LNCaP cells (Figure 3D), where the recovery of all cell 
population was similar after a 7-day treatment withdrawal 
(Figure 3D).
Enhanced self-renewal in TROP2high cells from 
androgen-independent prostate cancer cell lines
To determine whether high TROP2 expression also 
characterizes a sub-population of cells with enhanced 
resistance to high dose chemotherapy in androgen-
independent cells, we then characterized the TROP2high 
population in the PC3 and DU145 cell lines. Approximately 
2.7% of PC3 cells were found to highly express extracellular 
TROP2 (Figure 4). TROP2 mRNA was not enriched in 
TROP2high PC3 cells compared to other populations (Figure 
4B), but we found that the amount of TROP2 targeted to 
the extracellular membrane was indeed much higher in 
TROP2high cells than in any other populations (Figure 4C). 
Quantification using ELDA indicated that TROP2high PC3 
cells had higher spheroid forming capacity than ungated 
cells and TROP2low cells (Table 2 and Supplementary 
Figure S5). Similar results were obtained with TROP2high 
cells isolated from the androgen-independent cell line 
DU145 (Table 2 and Supplementary Figure S5). In addition, 
TROP2high PC3 cells showed high mRNA levels of cancer 
stem cell markers such as OCT4, ALDH1A3 and DCLK1.
Since the expression of TROP2 was previously 
shown to overlap with ALDH activity - a putative TIC 
marker of clinical relevance [18], we performed additional 
ELDAs to assess whether the high self-renewal ability of 
TROP2high PC3 cells was associated with their ALDH 
activity. However, we found that extracellular TROP2 
expression predicted the spheroid-forming frequency of 
PC3 sub-populations irrespective of their ALDH activity. 
Indeed, TROP2highALDHlow and TROP2highALDHhigh 
cells showed a similarly high sphere-forming frequency, 
indicating that their self-renewal ability is 5 to 10 
times higher compared to all other cell sub-populations 
within this cell line (Table 3). This suggests that TROP2 
expression is a better predictor of tumor-initiating 
properties than ALDH in these androgen-independent 
cells.
To investigate whether TROP2 expression is also 
associated with differential chemoresistance abilities 
in androgen-independent cells, we exposed PC3 and 
DU145 cells to docetaxel for 5 days, followed or not by 
a 7-day post-treatment withdrawal. Similar to what was 
found for androgen-sensitive cells, significantly lower 
numbers of viable cells were detected after post-treatment 
withdrawal compared to right after treatment cessation 
(Figure 4). No significant survival difference in cell 
viability between TROP2high and other cell populations 
was observed immediately after a 5-day treatment with 
the chemotherapeutic drug docetaxel for either of the two 
cell lines (Figure 4D–4E and Supplementary Figure S6–
S7). Seven days after withdrawal of this compound, the 
proportion of surviving TROP2low PC3 cells was lower 
than those in ungated and TROP2high PC3 cells (Figure 
4D and Supplementary Figure S6), but this was not the 
case for DU145 cells (Figure 4E and Supplementary 
Figure S7), suggesting that this may not be an overall 
characteristic of androgen-independent TROP2high cells. 
Taken together, these results indicate that the TROP2high 
population displays a stronger self-renewal potential than 
other cells in androgen-independent prostate cancer cells, 
but does not identify a cell sub-population with enhanced 
chemo-resistance ability.
Table 1: Sphere-forming efficiency of LNCaP and 22Rv1 cells sorted based on their extracellular Trop2 expression 
level, as calculated using the ELDA webtool
Cell population Sphere-forming frequency of androgen-sensitive prostate cancer cells
Estimate Confidence Interval
LNCaP - Ungated 1/11.4 1/10.6 – 1/13.5
LNCaP - Trop2high 1/15.9 1/13.3 – 1/18.7
LNCaP - Trop2low 1/18.9 1/16.1 – 1/22.3
22Rv1 - Ungated 1/8.3 1/4.9 – 1/13.9
22Rv1 - Trop2high 1/7.6 1/4.4 – 1/12.9
22Rv1 - Trop2low 1/11.2 1/6.6 – 1/19
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Figure 4: A. FACS profile of PC3 cells according to their surface TROP2 expression level. Black line: cells were stained mouse isotype 
control; red line: cells were stained with TROP2 antibody. B. RT-qPCR quantitation of TACSTD2 (TROP2), POU5F1 (Oct4), NKX3.1, 
ALDH1A3 and DCLK1 mRNA expression. C. IF staining for TROP2 on PC3 cells sorted as in (A). Scale bar = 50µM. D. Percentage of 
viable TROP2high, TROP2low and ungated PC3 cells at the end of a 5-day treatment with docetaxel (top) or following a 7-day recovery 
phase in docetaxel-free medium (bottom). Data represents the mean percentage of surviving cells after exposure to the three highest 
concentrations of docetaxel (1nM, 10nM, 100nM). E. Percentage of viable TROP2high, TROP2low and ungated PC3 cells at the end of a 5-day 
treatment with docetaxel (left) or following a 7-day recovery phase in docetaxel-free medium (right). Data represents the mean percentage 
of surviving cells after exposure to the three highest concentrations of docetaxel (1nM, 10nM, 100nM). In D and E: *, P < 0.05, ***, P < 
0.001, one-way ANOVA with Bonferroni post-hoc, n = 3);
Table 2: Sphere-forming efficiency of sorted PC3 and DU145 cells sorted based on extracellular Trop2 expression 
level, as calculated using the ELDA webtool 
Cell population Sphere-forming frequency of androgen-independent cells
Estimate Confidence Interval
PC3 - Ungated 1/51.5# 1/43.8 – 1/60.4
PC3 - Trop2high 1/18.2*# 1/15.4 – 1/21.4
PC3 - Trop2low 1/127.7* 1/104.5 – 1/156.0
DU145 - Ungated 1/25.2 1/14.5 – 1.39.5
DU145 - Trop2high 1/5.6*# 1/3.3 – 1/9.4
DU145 - Trop2low 1/18.2 1/11.1 – 1/30.1
*, significantly different from ungated population (P<0.0001); #, significantly different from Trop2low cells (P<0.0001, 
Pearson Chi-square test).
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A functional role for TROP2 in LNCaP cell post-
treatment recovery in vitro
To investigate whether TROP2 has a functional 
role in treatment resistance, androgen-independent 
PC3 cells and androgen-sensitive LNCaP cells were 
transfected with TROP2 siRNA to selectively down-
regulate TROP2 expression. The down-regulation of 
extracellular membrane TROP2 expression compared to 
cells transfected with a control siRNA was confirmed by 
flow cytometry and baseline growth was unaffected in 
cells transfected with TROP2 siRNAs (Supplementary 
Figure S8). No difference in cell viability was observed 
between control and TROP2 siRNA transfected PC3 cells 
immediately after 5-day docetaxel treatment (Figure 5A) 
or 7 days after docetaxel withdrawal from the culture 
medium (Figure 5B).
Treatment of LNCaP cells with docetaxel for 5 days 
affected the viability of both control and TROP2 siRNA-
transfected cells with a similar IC50, although survival in 
the presence of high docetaxel concentrations (with or 
without flutamide) was slightly reduced in TROP2 siRNA-
transfected cells compared to controls (Figure 5C). When 
LNCaP cells were maintained in culture for a further 7 
days after withdrawal of high docetaxel concentrations, 
cell recovery was significantly impaired in populations 
expressing TROP2 siRNA compared to controls (Figure 
5D). A similar trend, albeit non-significant, was observed 
in cells recovering from the combination (docetaxel + 
flutamide) treatment. (Figure 5D).
These findings suggest that TROP2 may play a role 
in the ability of androgen-sensitive, but not of androgen-
independent prostate cancer cells, to avoid cell death and/
or to recover from treatment following exposure to high 
concentrations of chemotherapeutics.
DISCUSSION
In the present study we demonstrate that high 
expression of cell-surface TROP2 is a marker of, and 
plays a functional role in the ability of androgen-sensitive 
prostate cancer cells to recover from docetaxel-based 
chemotherapy, and that high TROP2 expression is a 
marker of poor prognosis in patients with low-grade 
prostate tumors. In androgen-independent prostate cancer 
cells however, TROP2 does not appear to mark cells with 
enhanced treatment resistance ability but rather enriches 
cell sub-populations with high self-renewal potential, 
which represent a characteristic of cancer stem cells and 
progenitor cells.
We first found that androgen-sensitive LNCaP 
and 22Rv1 cells that exhibit high cell-surface TROP2 
expression recover more efficiently than other cell 
sub-populations following a 5-day treatment with 
high concentrations of docetaxel, as seen after a 7-day 
withdrawal phase in the absence of treatment. This 
result provided a cellular rationale in support of our 
in vivo results demonstrating the enriched presence of 
TROP2 mRNA and membrane TROP2 immunostaining 
in tumors that recur following treatment with docetaxel 
alone or in combination with flutamide. Highlighting 
the clinical significance of our findings, these results are 
in accordance with our observation that high TROP2 
expression correlates with poor prognosis in cohorts of 
prostate cancer patients, particularly in patients with low 
(Gleason 6) grade tumors. Extracellular expression of 
TROP2 has been found to correlate with poor prognosis in 
other cancers including breast [19], gastric [20] as well as 
gliomas [21], suggesting that TROP may also represent a 
functional marker for cell sub-populations with enhanced 
ability to avoid cell death and/or to recover from treatment 
in these cancers.
Flutamide weakly but significantly slowed the 
growth of LNCaP xenografts in vivo when used alone, a 
result seemingly at odds with a reports demonstrating it 
can act as a partial agonist on cells carrying a mutated 
version of the androgen receptor, such as LNCaP cells 
[17, 22]. However, the agonist activity of flutamide is 
most readily measured in the absence of endogenous 
ligands, and we suggest that competition of flutamide 
Table 3: spheroid-forming efficiency of sorted PC3 cells according to their surface Trop2 expression and ALDH 
activity, as calculated using the ELDA webtool
Cell population Sphere-forming frequency
Estimate Confidence Interval
Ungated 1/62.6 1/49.5 - 1/79.1
ALDHhighTrop2high 1/16.8* 1/13.3 – 1/21.2
ALDHhighTrop2medium 1/129.3 1/97.3 – 1/171.7
ALDHlowTrop2high 1/13.3* 1/10.5 – 1/16.9
ALDHlowTrop2medium 1/74.8 1/58.7 – 1/95.3
ALDHlowTrop2low 1/182.0 1/131.9 – 1/251.2
*, significantly different from Trop2medium and Trop2low populations (P<0.0001, Pearson Chi-square test).
Oncotarget44500www.impactjournals.com/oncotarget
with endogenous androgens such as di-hydro testosterone 
for receptor binding may have contributed to this apparent 
growth reduction, as flutamide is not as potent an agonist 
as DHT [23]. Similar reversion of DHT-induced LNCaP 
cell growth by flutamide has been shown to occur in vitro 
[24]. Newer generation antagonists such as bicalutamide 
and enzalutamide, which are effective against the mutated 
receptor and do not have agonistic activity against LNCaP 
cells [25, 26], would most likely produce a more robust 
antitumour effect.
Because tumor-initiating/cancer stem cells have 
been suspected to play a role in androgen ablation and 
chemotherapy resistance as well as post-treatment 
prostate cancer relapse [27], we also analyzed whether 
the enhanced treatment recovery displayed by TROP2high 
cells was associated with high self-renewal ability. 
However we did not find any difference between the self-
renewal ability of TROP2high, TROP2low and ungated cells 
from the LNCaP and 22Rv1 cell lines, suggesting that 
the androgen-sensitive cells that emerge post-treatment 
may not necessarily bear intrinsic cancer stem cell 
characteristics. Accordingly the expression of candidate 
prostate cancer stem cell markers such as CD49f [11] 
and CD44 [28](not shown) was not found to be elevated 
in TROP2high LNCaP cells in vitro or in post-treatment 
recurring LNCaP xenografts in vivo.
In addition, we found that transfecting cells with 
TROP2 siRNA significantly reduced the percentage of 
viable LNCaP cells 7 days after docetaxel withdrawal, 
suggesting that the TROP2 glycoprotein itself may play 
an active role in the recovery process of these cells after 
chemotherapy androgen ablation and treatments. Down-
regulation of TROP2 was previously shown to inhibit 
chemotherapy-induced keratinocyte apoptosis [29] and a 
TROP2-targeting approach demonstrated robust antitumor 
activity in triple-negative breast cancer [30]. Our current 
findings suggest that targeting TROP2 in combination 
with chemotherapy may improve treatment efficiency in 
androgen-sensitive prostate tumors.
In contrast, TROP2 siRNA transfection failed to 
alter PC3 cell viability in response to docetaxel treatment, 
in accordance with the lack of observed capacity for 
TROP2high cells to recover more efficiently after treatment 
in androgen-independent cells. This results suggests that 
the apparent dependency of androgen-sensitive cells upon 
TROP2 to improve recovery from cytotoxic treatment 
may be lost during progression towards the androgen-
independent stage, at which point prostate tumors are 
reported to be more aggressive and chemotherapies such 
as docetaxel are known to be poorly effective overall [3]. 
Nevertheless, we found that androgen-independent PC3 
and DU145 cells expressing high levels of extracellular 
TROP2 have higher sphere-forming efficiency than 
TROP2low and ungated cells. The capacity to self-renew 
is a critical property of tumor-initiating cells, fuelling 
the long-term maintenance of malignant clones [31]. 
Under spheroid culture conditions, which are known to 
promote self-renewal in various cancers [32], TROP2high 
PC3 cells consistently generated TROP2high cells only 
(Supplementary Figure S9), highlighting their capability to 
Figure 5: A–B. Percentage of viable PC3 cells transfected with control or TROP2-specific siRNA at the end of a 5-day treatment with 
docetaxel (A) or following a 7-day recovery phase in docetaxel-free medium (B). C–D. Percentage of viable LNCaP cells transfected with 
control or TROP2-specific siRNA and with docetaxel alone or in combination with flutamide (as indicated), at the end of a 5-day treatment 
(C) or following a 7-day recovery phase in docetaxel-free medium (D). P values are indicated (t-test, n = 3).
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self-renew without differentiating and thus demonstrating 
that the phenotype of these self-renewing cells is stable 
under such conditions. In contrast, under the same 
self-renewal-promoting culture conditions, TROP2low 
PC3 cells were able to produce a small population of 
TROP2high cells (Supplementary Figure S9), corroborating 
prior demonstrations of plastic transition from non-stem 
to stem-like phenotypes in non-neoplasic and cancer 
cells [33]. These results suggest that TROP2high PC3 
cells display a tumor-initiating cell-like phenotype, 
complementing previous reports that identified TROP2 as 
a promoter of stemness in the normal prostate epithelium 
[11, 12] but linking it to an androgen-independent 
phenotype. Our results show that in PC3 cells, self-
renewability is associated with extracellular expression 
of TROP2 independently from ALDH activity. Cells with 
high ALDH activity have been proposed to have tumor-
initiating activity in several solid cancers including colon, 
breast, liver, ovarian and pancreatic cancer [34], but in 
the present study ALDH activity-based selection did not 
enrich for PC3 cells with enhanced self-renewal in vitro 
(Table 3) or enhanced tumor-initiating ability in vivo 
(Supplementary Table S1).
In summary, while extracellular TROP2 
overexpression had previously been reported to enhance 
prostate cancer cell migration and metastatic ability [35] 
and to correlate with prostate cancer aggressiveness [13], 
results of the present study provide the first demonstration 
that high membrane TROP2 expression characterizes 
different cell subpopulations in androgen-sensitive and 
androgen-independent prostate cancer cells. We identified 
androgen-dependent TROP2high cells as a population of 
cells that drives post-treatment re-growth, while high 
membrane TROP2 expression represents a hallmark of 
self-renewing TICs in aggressive androgen-independent 
tumor cells. Thus, our results suggest that extracellular 
TROP2 expression could serve as a prognostic indicator 
of treatment outcome in prostate cancer, and that targeting 
cancer cells with high surface expression of TROP2 
may be an effective way to prevent progression towards 
castration resistant prostate cancer.
MATERIALS AND METHODS
Immunohistochemistry
Human prostate cancer tissue sections
Slides of human prostate cancer tissues 
were obtained and stained under ethics agreement 
HREC2012.275 (Royal Melbourne Hospital, Melbourne, 
Australia). Sections were dewaxed, rehydrated and antigen 
retrieval was performed for 15 min in Citrate buffer (pH 
6.10). Endogenous peroxidase activity was blocked using 
3% H2O2 in MetOH for 20min at room temperature. 
Slides were incubated for 2h in blocking buffer alone, 
followed by an overnight incubation at 4C in blocking 
buffer containing anti-TROP2 or isotype antibodies (BD 
Bioscience 551317, 1/500). Biotinylated anti-mouse 
secondary antibody (1/500, AbCAM) was incubated 
for 30 min at room temperature, followed by Tyramide 
Signal Amplification (TSA)(Perkin Elmer, Melbourne, 
Australia), revelation with diaminobenzidine (DAB) 
detection kit (AbCAM, Melbourne, Australia), Ethanol/
Xylene dehydration and mounting. The percentage of cells 
considered as positive for TROP2 staining (cf example in 
Figure 1A) was calculated after counting positive and total 
cell numbers in 5 randomly chosen fields of approximately 
100 tumor cells.
Tumor xenografts
Slide-mounted cryo-cut tumor sections were 
fixed with 4% paraformaldehyde for 10 minutes and 
stained with mouse anti-human TROP2 antibody (BD 
Bioscience 551317, 1/200) overnight at 4°C followed by 
incubation with fluorescein horse anti-mouse IgG (Vector 
laboratories, 1/200) for 1 hour at room temperature. 
Hoechst 33342 (Invitrogen) was used to stain nuclei. 
Fluorescent images were taken with a Nikon digital 
camera attached to a Nikon A1R confocal microscope 
(Nikon).
SurvExpress data analysis
The correlation between TROP2 expression and 
disease outcome was analyzed using the SurvExpress 
bioresource [14] (http://bioinformatica.mty.itesm.mx:8080/
Biomatec/SurvivaX.jsp). Selected datasets were originally 
from the Gene Expression Omnibus (GSE16560, 281 
patients [16], and GSE40272, 98 patients [15]). Selection 
criteria included minimal patient number per study (>80), 
presence of TACSTD2 (TROP2)-specific probes, and 
availability of survival and/or recurrence-free survival 
data. Presented data summarizes TROP2 expression levels 
(median, 5-95 percentile) and Kaplan-Meier analysis 
(Hazard ratio) of survival or recurrence-free survival as 
indicated in high and low risk patient subgroups. Optimized 
risk scores were determined as described in [14].
LNCaP xenografts
NOD/SCID mice were obtained from the Monash 
Animal Research Platform and ethical approval for in vivo 
experiments was obtained from the Monash University 
Standing Committee on Ethics in Animal Experimentation 
(Ethics numbers: VCPA.2010.33 and MIPS.2012.15).
LNCaP cells (1x106) were injected subcutaneously 
into the left flank of NOD/SCID mice and treatments were 
initiated once tumors reached a volume of 100mm3. The 
timeline for the experiment is provided in Supplementary 
Figure S1, with the different treatment groups as follows: 
The control group received a slow-releasing pellet 
containing placebo and an intra-venous injection of vehicle; 
the flutamide group (chemical androgen ablation) received 
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33mg/kg/day flutamide and an intra-venous injection 
of vehicle once a week for four weeks; the docetaxel 
chemotherapy group received a placebo pellet and an intra-
venous injection of 10mg/kg docetaxel once a week for 
four weeks; The Combined group (flutamide + docetaxel) 
received a combination of the flutamide and docetaxel 
doses indicated above. Flutamide treatment was performed 
by implanting a slow-release flutamide pellet on the lateral 
side of the neck of the mouse. An incision equal in diameter 
to that of the pellet (approximately 6mm) was made using 
sterile surgical scissors. A pocket horizontal to the cut was 
made using blunt forceps about 2cm beyond the incision 
site. A slow-releasing flutamide pellet (100mg for 90-days 
releasing 33mg/kg/day, Innovative Research of America) or 
placebo pellet (Innovative Research of America) was placed 
into the pocket with forceps and angled to the right on the 
lateral side of the neck between the ear and shoulder where 
there is maximal space between the skin and muscle. The 
incision site was then sealed with 9mm BBL™ AUTOCLIP 
wound clips (BD Diagnostics).
Stock solutions of 20mg/ml docetaxel (Tocris) were 
prepared in 100% ethanol. A final dilution was made just 
prior to injection in a vehicle of Tween 80 (Sigma) and 5% 
dextrose (5/5/90 vol/vol/vol).
Mice treated with docetaxel or combination therapy 
were culled when tumor relapse had occurred, defined by 
an increase in tumor size in two consecutive measurements 
following the end of treatment. Due to slight variations in 
treatment response among individual mice, individual 
animals were culled at slightly different time points. In 
control and androgen ablation groups, mice were culled 49 
days after the beginning of treatment when the first mouse in 
the control group had to be culled when tumors had grown 
to a diameter of >12mm, as per ethical requirements (n=5).
Cell culture
Human prostate cancer cell lines PC3 (CRL-1435) 
and LNCaP (CRL-1740), DU145 (HTB-81) were obtained 
from American Type Culture Collection (ATCC) and 
cultured in Ham’s F-12K (Invitrogen) or RPMI medium 
1640 (Invitrogen). The 22Rv1 cell line (CRL-2505) was 
obtained from Prof. Martin Lackmann (Department of 
Biochemistry, Monash University, Melbourne, Australia). 
Media for all cell lines was supplemented with 10% 
Fetal Bovine Serum (FBS) (Invitrogen 10100-147). The 
usual androgen concentration within FBS (0.1–1 nM Di 
Hydro Testosterone) is sufficient to efficiently maintain 
androgen-sensitive cells such as LNCAP and 22RV1 [36].
For spheroid culture, cells were grown in serum-free 
DMEM/F-12 medium (Invitrogen 10565) supplemented 
with 1% N2 (Invitrogen 17502-048), 2% B27 (Invitrogen 
17504-044), 20 ng/mL human epidermal growth factor 
(EGF Invitrogen PHG0311), 20ng/mL human fibroblast 
growth factor-basic (FGF-b Invitrogen PHG0026) and 100 
units of Penicillin-Streptomycin (Invitrogen) in ultra-low 
attachment plates (Costar).
FACS analysis and sorting
Cells were stained with Mouse anti-human TROP2 
antibody (BD Bioscience 551317, 1/200) in antibody 
staining buffer (0.9% (w/v), sodium azide and 2% FBS 
in PBS) for 1 hour. Following three washes in PBS, Alexa 
Fluor® 647 Goat Anti-Mouse IgG secondary antibody 
(Invitrogen A21236, diluted 1 in 1000 in antibody staining 
buffer) was incubated for one hour at 4°C. Stained cells 
were then washed three times in antibody staining buffer 
prior to FACS sorting and analyzing.
Cell sorting was performed using a 
MoFlo®AstriosTM (Beckman Coulter). The gating 
strategy to define negative populations for ALDH and 
TROP2 staining was designed so as to include at least 
99.9% of cells in the DEAB and isotype negative control 
samples. A distinct population highly expressing TROP2 
was identified and sorted from PC3 cells (~2.75% of total 
viable cells). The same gating strategy was applied to 
LNCaP, DU145 and 22Rv1 cells. Since no individualized 
TROPhigh population was detected in these cell lines, 
the TROP2high population was defined as the top 2% of 
TROP2-expressing cells. FACS analysis was performed 
using a FACSCanto™ II (BD Science).
RT-qPCR
mRNA levels for ten genes that were previously 
reported to act as prostate stem cell or TIC markers or that 
are involved in cancer progression and metastasis (CD44, 
ITGA6 (aka CD49f), TACSTD2 (TROP2), POU5F1 (OCT3-
4), NKX3.1, CTNNB1 (beta-catenin), DCLK1, DICER, AKT, 
ALDH1A3) were detected by qPCR in both sorted cells and 
tumor tissues by RT-qPCR. RNA from both tissue and cells 
was extracted using the RNeasy Plus Micro kit (Qiagen) 
following the manufacturer’s instructions. Real-time RT-
qPCR was carried out with pre-designed human TAQMAN® 
probes (Invitrogen) with iScript™ One-Step RT-PCR 
Kit (Bio-Rad) in a CFX96™ Real-Time PCR Detection 
System (Bio-Rad)., For both PC3 and LNCaP cell lines, 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was 
used as a housekeeping gene, while, the ribosomal proteins 
RPLP0 and RPLR30 were used for tumors derived from PC3 
and LNCaP xenografts respectively.
Extreme limiting dilution assay (ELDA)
Cells were sorted and seeded in 3 different 
concentrations: 10 cells/well, 30 cells/well and 100 cells/
well in low-attachment 96-well plates in spheroid culture 
medium. For each individual experiment, 120 replicates 
were performed for each concentration of cells. The 
presence or absence of spheroids (included in the count 
when size >50µm diameter) in each well was determined 
at day 14 using a conventional light microscope (Nikon). 
When run under these conditions, ELDA provides a robust 
estimate of the tumor-initiating cell frequency, calculated 
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and analyzed using the ELDA webtool (http://bioinf.wehi.
edu.au/software/elda)[37].
In vitro toxicity assays
Cells were treated with various concentrations of 
docetaxel for 5 days and washed three times with PBS 
at the end of treatment. Cells were then cultured in their 
ordinary culture medium without docetaxel for 7 days 
before being tested for cell viability. For the combination 
treatment, 10µM of flutamide remained in the medium 
after the withdrawal of docetaxel. Cell viability was 
assessed using the CellTiter®-Blue cell viability assay 
(Promega) according to the manufacturer’s instructions.
siRNA transfection
Both PC3 and LNCaP cells were transfected 
with TROP2-target siRNA (Taqman Silencer® Select 
siRNA, Thermofisher, https://www.thermofisher.com/
order/genome-database/details/sirna/s8366, 50nM final 
concentration) for 24 hours. Cells were then detached and 
seeded in 96-well plates 24 hours prior to treatment.
Data analysis
For each in vitro experiment, at least three different 
passages of cells were used independently in triplicate 
(n=3). For in vivo experiments, 5 mice were used in each 
experimental group. Data was expressed as Mean ± S.E.M 
and analyzed using two-way ANOVA with Bonferroni’s 
Post Hoc Test for multiple comparisons using Graph Pad 
Prism 5.0. A P value < 0.05 was considered statistically 
significant. For ELDA assay, data was analyzed with the 
ELDA webtool (http://bioinf.wehi.edu.au/software/elda/
index.html) using a Pearson Chi-square test and a P value 
< 0.05 was considered statistically significant.
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